The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias

New England Journal of Medicine

Volumn 319, Issue 15, 1988, Pages 990-998

  Epstein, Franklin H ^a   Kurzrock, Razelle ^b   Gutterman, Jordan U ^b   Talpaz, Moshe ^b  

^a University of Texas MD Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANIMAL; HUMAN; LEUKEMIA; LEUKEMIA, MYELOID; MICE; ONCOGENES; PHILADELPHIA CHROMOSOME; PROTO-ONCOGENES; SUPPORT, NON-U.S. GOV'T;

EID: 0023753576     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198810133191506     Document Type: Review

References (75)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–3.
3. Rowley Chromosome abnormalities in human leukemia. Annu Rev Genet 1980; 14: 17–39.
4. Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1981; 4: 111–37.
5. Whang-Peng J, Henderson RS, Knutsen T, Freireich EJ, Gart JJ. Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of the Ph1 chromosome. Blood 1970; 36: 448–57.
6. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of the c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 1983; 306: 277–80.
7. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306: 239–42.
8. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–9.
9. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 1985; 315: 758–61.
10. Rodenhuis S, Smets LA, Slater RM, Behrendt H, Veerman AJP. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia. N Engl J Med 1985; 313: 51–2.
11. Erikson J, Griffin CA, ar-Rushdi A, et al. Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph1+) acute lymphocytic leukemia. Proc Natl Acad Sci USA 1986; 83: 1807–11.
12. De Klein A, Hagemeijer A, Bartram CT, et al. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369–75.
13. Kurzrock R, Shtalrid M, Gutterman JU, et al. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. Br J Haematol 1987; 67: 55–9.
14. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987; 70: 1584–8.
15. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125–30.
16. Sonta SI, Sandberg AA. Chromosomes and causation of human cancer and leukemia. XXIV. Unusual and complex Ph1 translocations and their clinical significance. Blood 1977; 50: 691–7.
17. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–35.
18. Nowell PC, Jackson L, Weiss R, Kurzrock R. A case of Ph1-positive chronic myelogenous leukemia followed for 27 years. Cancer Genet Cytogenet (in press).
19. Look AT. The emerging genetics of acute lymphoblastic leukemia: clinical and biologic implications. Semin Oncol 1985; 12: 92–104.
20. Catovsky D. Ph1-positive acute leukaemia and chronic granulocytic leukaemia: one or two diseases? Br J Haematol 1979; 42: 493–8.
21. Jain K, Arlin Z, Mertelsmann R, et al. Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation. J Clin Oncol 1983; 1: 669–76.
22. Hoffmann FM, Fresco LD, Hoffman-Falk H, Shilo BZ. Nucleotide sequences of the Drosophila src and abl homologs: conservation and variability in the src family oncogenes. Cell 1983; 35: 393–401.
23. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 1987; 7: 3231–6.
24. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550–4.
25. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr–abl fused gene. Cell 1986; 47: 277–84.
26. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Alternative 5′ exons in c-abl mRNA. Cell 1986; 44: 577–86.
27. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116–23.
28. Hunter T, Cooper JA. Protein-tyrosine kinases. Annu Rev Biochem 1985; 54: 897–930.
29. Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 1970; 30: 2213–22.
30. Whitlock CA, Witte ON. The complexity of virus–cell interactions in Abelson virus infection of lymphoid and other hematopoietic cells. Adv Immunol 1985; 37: 73–98.
31. Konopka JB, Wine ON. Activation of the abl oncogene in murine and human leukemias. Biochim Biophys Acta 1985; 823: 1–17.
32. Prywes R, Foulkes JG, Baltimore D. The minimum transforming region of c-abl is the segment encoding protein-tyrosine kinase. J Virol 1985; 54: 114–22.
33. Hariharan IK, Adams JM. cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia. EMBO J 1987; 6: 115–9.
34. Mes-Masson AM, McLaughlin J, Daley GQ, Paskind M, Witte ON. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci USA 1986; 83: 9768–72.
35. Stam K, Heisterkamp N, Reynolds FH Jr, Groffen J. Evidence that the Ph1 gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol 1987; 7: 1955–60.
36. Collins SJ. Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML): amplification of rearranged c-abl oncogenes in CML blast crisis. J Clin Invest 1986; 78: 1392–6.
37. Schaefer-Rego K, Dudek H, Popenoe D, et al. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood 1987; 70: 448–55.
38. Boehm TL, Drahovsky D. Application of a bcr-specific probe in the classification of human leukaemia. J Cancer Res Clin Oncol 1987; 113: 267–72.
39. Shtalrid M, Talpaz M, Kurzrock R, et al. Analysis of bcr gene and correlation with clinical course in Ph-positive chronic myelogenous leukemia. Blood 1988; 72: 485–91.
40. Selleri L, Narni F, Emilia G, et al. Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region. Blood 1987; 70: 1659–64.
41. Benn P, Soper L, Eisenberg A, et al. Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Genet Cytogenet 1987; 29: 1–7.
42. Hirosawa S, Aoki N, Shibuya M, Onozawa Y. Breakpoints in Philadelphia chromosome (Ph1)-positive leukemias. Jpn J Cancer Res 1987; 78: 590–5.
43. Kurzrock R, Shtalrid M, Romero R, et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 1987; 325: 631–5.
44. Clark SS, McLaughlin J, Crist WM, Champlin TR, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235: 85–8.
45. Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635–7.
46. Walker LC, Ganesan TS, Dhut S, et al. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 1987; 329: 851–3.
47. Hermans A, Heisterkamp N, von Linden M, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33–40.
48. Okabe M, Matsushima S, Morioka M, et al. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Blood 1987; 69: 990–8.
49. Schaefer-Rego K, Arlin Z, Shapiro LG, Mears JG, Leibowitz D. Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Res 1988; 48: 866–9.
50. Popencoe DW, Schaefer-Rego K, Mears JG, Bank A, Leibowitz D. Frequent and extensive deletion during the 9,22 translocation in CML. Blood 1986; 68: 1123–8.
51. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035–42.
52. Kloetzer W, Kurzrock R, Smith L, et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985; 140: 230–8.
53. Kurzrock R, Kloetzer WS, Talpaz M, et al. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood 1987; 70: 233–6.
54. Maxwell SA, Kurzrock R, Parsons SJ, et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 1987; 47: 1731–9.
55. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the p210 bcr/abl oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558–62.
56. Ezdinli EZ, Sokal JE, Crosswhite L, Sandberg AA. Philadelphia-chromosome–positive and -negative chronic meylocytic leukemia. Ann Intern Med 1970; 72: 175–82.
57. Pugh WC, Pearson M, Vardiman JW, Rowley JD. Philadelphia chromosome-negative chronic myelogenous leukemia: a morphological reassessment. Br J Haematol 1985; 60: 457–67.
58. Kurzrock R, Blick MB, Talpaz M, et al. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann Intern Med 1986; 105: 673–9.
59. Bartram CR, Kleihauer E, de Klein A, et al. C-abl and bcr are rearranged in a Ph1-negative CML patient. EMBO J 1985; 4: 683–6.
60. Morris CM, Reeve AE, Fitzgerald PH, Hollings PE, Beard ME, Heaton DC. Genomic diversity correlates with clinical variation in Ph1-negative chronic myeloid leukaemia. Nature 1986; 320: 281–3.
61. Bartram CR. bcr rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia. J Exp Med 1985; 162: 2175–9.
62. Dreazen O, Klisak I, Rassool F, Goldman JM, Sparkes RS, Gale RP. Do oncogenes determine clinical features in chronic myeloid leukaemia? Lancet 1987; 1: 1402–5.
63. Wiedemann LM, Karhi KK, Shivji MK, et al. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71: 349–55.
64. Shtalrid M, Talpaz M, Blick M, et al. Philadelphia-negative chronic myelogenous leukemia with bcr rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol (in press).
65. ar-Rushdi A, Negrini M, Kurzrock R, Huebner K, Croce CM. Fusion of the bcr and c-abl genes in Ph1-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region. Oncogene 1988; 2: 353–7.
66. Dreazen O, Berman M, Gale RP. Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. Blood 1988; 71: 797–9.
67. Rowley JD. Ph1-positive leukemia including chronic myelogenous leukemia. Clin Haematol 1980; 9: 55–86.
68. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824–7.
69. McCarthy DM, Rassool FV, Goldman JM, Graham SV, Birnie GD. Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia. Lancet 1984; 2: 1362–5.
70. Blick M, Romero P, Talpaz M, et al. Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet 1987; 27: 349–56.
71. Collins SJ, Kubonishi I, Miyoshi I, Groukine M. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science 1984; 225: 72–4.
72. Shtivelman E, Gale RP, Dreazen O, et al. bcr–abl RNA in patients with chronic myelogenous leukemia. Blood 1987; 69: 971–3.
73. Bartram CR, Janssen JW, Becher R, De Klein A, Grosveld G. Persistence of chronic myelocytic leukemia despite delegation of rearranged bcr–abl sequences in blast crisis. J Exp Med 1986; 164: 1389–96.
74. Griffin CA, McKeon C, Israel MA, et al. Comparison of constitutional and tumor-associated 11;22 translocation: nonidentical breakpoints on chromosomes 11 and 22. Proc Natl Acad Sci USA 1986; 83: 6122–6.
75. Bell JC, Mahadevan LC, Colledge WH, Frackelton AR Jr, Sargent MG, Foulkes JG. Abelson-transformed fibroblasts contain nuclear phosphotyrosyl-proteins which preferentially bind to murine DNA. Nature 1987; 325: 552–4.